ALK

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
星期二, 五月 7, 2024
FDA, Mayo Clinic, Nature Communications, Anaplastic lymphoma kinase, Cholangiocarcinoma, Research, Disease, Clinical professor, Patient, AACR, ALK, EGFR, NSCLC, Ovarian cancer, AstraZeneca, Platinum, Lung cancer, Pharmaceutical industry

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "Our clinical development programs for NXP800 and NXP900 continued to advance nicely in the first quarter of 2024.

Key Points: 
  • Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "Our clinical development programs for NXP800 and NXP900 continued to advance nicely in the first quarter of 2024.
  • For NXP800, we announced encouraging preliminary data from the Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer.
  • Cash, and cash equivalents were $19.5 million as of March 31, 2024, compared to $19.1 million as of December 31, 2023.
  • Net loss for the first quarter of 2024 fiscal year included $1.3 million in non-cash stock-based compensation.

Global $46.7B Cancer Biomarkers Market Outlook, 2035: MET Biomarkers Lead the Charge, Driven by Rising Incidence of Lung Cancer and Drug Development - ResearchAndMarkets.com

Retrieved on: 
星期三, 五月 8, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Foundation Medicine, MSI, Lung cancer, Breast cancer, Blood, AI, MDPI, Skin cancer, Agilent Technologies, Prostate cancer, Biomarker, ALK, Kidney cancer, EGFR, OncoDNA, Cancer, Bladder cancer, Tempus, Son, Non-small-cell lung cancer, Frontiers Media, HER2, Colorectal cancer, Turbine, Thyroid cancer, ARUP Laboratories, Roche, Database, Therapy, Merck, NSCLC, Thermo Fisher Scientific, Nature, Publication, Laboratory, Survival, Insurance, BioMed Central, Nature Portfolio, Incidence, Drug development, Liver cancer, Liquid biopsy, MET, NTRK, CK Life Sciences, Endometrial cancer, Actuate, PD-L1, Patient, Gastrointestinal cancer, Physician, Neoplasm, Head, Medical imaging

Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.

Key Points: 
  • Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.
  • Currently, the market is driven by breast cancer biomarkers and lung cancer biomarkers; however, in the coming future, we anticipate cancer biomarker market for leukemia to grow at a significant pace.
  • The market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in the cancer biomarkers market.
  • It is worth mentioning that Merck is conducting the maximum number of trials in this industry for various cancer indications, including bladder cancer, breast cancer, colorectal cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer and skin cancer.

Three-month interim report (Q1) 2024 (unaudited) 

Retrieved on: 
星期四, 五月 2, 2024
ALK, DKK, Growth, Capital market

Launch preparations continue to progress as planned ahead of the expected launches in 2024/25.

Key Points: 
  • Launch preparations continue to progress as planned ahead of the expected launches in 2024/25.
  • ALK is implementing a number of optimisation and prioritisation initiatives in 2024 to free up approximately DKK 250 million in 2025 for strategic growth investments and support of its earnings ambitions.
  • These initiatives are expected to entail one-off costs of approximately DKK 60 million in 2024, that have been included in the earnings outlook which is unchanged.
  • Commenting on the Q1 results, CEO Peter Halling said: “2024 started well for ALK.

Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting

Retrieved on: 
星期一, 四月 29, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, PFS, Brentuximab vedotin, Triple-negative breast cancer, Lung cancer, MBC, ASCO, Lymphoma, PFE, Metastasis, ALK, Breast cancer, Learning, CRS, Food, Colorectal cancer, Abstract, RRMM, Rituximab, ADC, HR, CDK4, De novo, Spacecraft, DLBCL, Tucatinib, Anaplastic lymphoma kinase, Safety, Crizotinib, Pembrolizumab, Survival, EZH2, Pros, Inc., Neoplasm, Progression-free survival, Recurrence, PAL, Biologics license application, HRR, Hodgkin lymphoma, Patient, Society, Cyclin-dependent kinase 4, Cytokine release syndrome, Annual general meeting, APLS, PBC, Lenalidomide, B-cell lymphoma, Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.
  • “We are excited to participate in our first ASCO Annual Meeting following the creation of Pfizer’s new Oncology organization, where we will highlight our efforts to accelerate breakthrough medicines that help people with cancer live better and longer lives,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • An oral presentation on extended duration of response from the Phase 3 MOUNTAINEER trial adds to the positive profile of TUKYSA in colorectal cancer.
  • Those interested in learning more can visit www.Pfizer.com/apls to access the summaries starting Friday, May 24.

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Retrieved on: 
星期二, 四月 23, 2024
Biotechnology, Pharmaceutical, Health, Oncology, PFS, Patient, Paclitaxel, Hospital, Food, European Commission, Neutropenia, JAMA Oncology, Survival, BGNE, Tislelizumab, Docetaxel, ESCC, European, Disease, Journal, Pemetrexed, Leukopenia, Neoplasm, Civil service commission, Carboplatin, ALK, EGFR, NSCLC, European Medicines Agency, Overalls, Lung cancer, Pharmaceutical industry

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use.

Key Points: 
  • BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use.
  • “Today’s EC authorization marks the second in the region for tislelizumab, with both NSCLC and locally advanced or metastatic esophageal squamous cell carcinoma now approved in the European Union.
  • As monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC after prior platinum-based therapy.
  • Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab.

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Retrieved on: 
星期一, 四月 22, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, Education, National Cancer Center, MET, D.C, Lung cancer, Woman, PMID, Progression-free survival, Harmonic, Machine learning, AME Publishing Company, ClinicalTrials.gov, Collection, Artificial intelligence, IPhone, Adenocarcinoma, ROS1, Disease, Incidence, Patient, Pemetrexed, TMB, SOC, Neoplasm, Lung, ALK, EGFR, NSCLC, Carboplatin, Overalls, Gene, TK, Pharmaceutical industry

Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).

Key Points: 
  • Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).
  • LCINS are histologically, mutationally, and epidemiologically distinct from smoking-related lung cancers and occur almost exclusively as adenocarcinomas and most commonly in women and individuals of Asian ancestry.
  • Dr. Goto will now lead the trial in Japan, where the incidence of non-small cell lung cancer (NSCLC) in never-smokers is double or more than that of the United States.
  • In addition, LP-300 has been administered in multiple clinical trials to more than 1,000 people and has been generally well tolerated.

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

Retrieved on: 
星期四, 四月 18, 2024
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Phase, Cancer, Anaplastic lymphoma kinase, Risk, Food, ROG, Death, Recurrence, Roche, Disease, Patient, Neoplasm, Biomarker, ALK, NSCLC, Alectinib, Lung cancer, Pharmaceutical industry

Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumor.

Key Points: 
  • Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumor.
  • “At Genentech, our goal is to give patients the best chance of cure by bringing effective, targeted treatments to early-stage disease before their cancer has spread.
  • In an exploratory analysis, an improvement of central nervous system (CNS)-disease-free survival (DFS) was observed (HR=0.22; 95% CI: 0.08-0.58).
  • Alecensa is a kinase inhibitor currently approved as first- and second-line treatment for ALK-positive metastatic NSCLC.

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Retrieved on: 
星期二, 四月 16, 2024
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Radiation, CMS, Pharmacy, Refrigeration, Hospital, Pembrolizumab, Cisplatin, Aplastic anemia, Mesothelioma, Disease, Restrictive lung disease, Pemetrexed, Patient, Medicare, Kidney, ALK, Medication, Amneal Pharmaceuticals, RTU, Pharmaceutical industry

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the launch of PEMRYDI RTU®, the first and only ready-to-use presentation of pemetrexed for injection.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the launch of PEMRYDI RTU®, the first and only ready-to-use presentation of pemetrexed for injection.
  • This product does not require reconstitution, dilution, or refrigeration, which is different than other versions of pemetrexed for injection.
  • “The launch of PEMRYDI RTU highlights Amneal’s deep commitment to oncology as we invest to develop injectable products that are important to healthcare providers and patients,” said Sean McGowan, Vice President, Biosimilars and Branded Oncology.
  • PEMRYDI RTU® injectable is available in two vial sizes: 100mg/10mL and 500 mg/50mL.

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Retrieved on: 
星期一, 四月 8, 2024
EGFR, Patient, Anaplastic lymphoma kinase, Research, Alectinib, Active ingredient, Lung cancer, AACR, AstraZeneca, ALK, Vaccine

Fort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (EGFR)-resistant non-small cell lung cancer (NSCLC) cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved for the treatment of NSCLC. The data reported, which confirms data previously published by the research team at Astra Zeneca, demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone.

Key Points: 
  • The data reported, which confirms data previously published by the research team at Astra Zeneca, demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone.
  • In addition, NXP900 demonstrated potent, single agent, antiproliferative activity in anaplastic lymphoma kinase (ALK)-resistant NSCLC cells and synergistic effects in combination with alectinib in alectinib sensitive cells.
  • Alectinib is the active ingredient in AlecensaTM, an ALK inhibitor approved for the treatment of NSCLC.
  • Moreover, effective inhibition of signaling pathways associated with osimertinib and alectinib resistance were observed in the respective cell lines tested.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
星期二, 四月 9, 2024
Lung, TUSC2, Agonal respiration, Metabolism, Gene, Apoptosis, Cell, NSCLC, Nanoparticle, Patient, Neoplasm, Research, Pembrolizumab, Date, NPRL2, Lung cancer, Immunity, ATP, ALK, Glycolysis

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which is being held April 5-10, 2024 in San Diego, California.

Key Points: 
  • Alectinib is an ALK-inhibitor commonly used to treat patients with ALK rearrangements such as EML4-ALK positive NSCLCs.
  • This research suggests that REQORSA may be an effective treatment in patients progressing on alectinib.
  • The study found that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect.
  • Study findings suggest that NPRL2 gene therapy induces anti-tumor activity against KRAS/STK11mt tumors through dendritic cell-mediated antigen presentation and cytotoxic immune cell activation.